-
1
-
-
0021978223
-
Tumor angiogenesis
-
Folkman J (1985) Tumor angiogenesis. Adv Cancer Res 43:175-203
-
(1985)
Adv Cancer Res
, vol.43
, pp. 175-203
-
-
Folkman, J.1
-
2
-
-
84959830787
-
Vascular reactions of normal and malignant tissue in vivo
-
Algire GH, Chalkley HW (1945) Vascular reactions of normal and malignant tissue in vivo. J Natl Cancer Inst 6:73-85
-
(1945)
J Natl Cancer Inst
, vol.6
, pp. 73-85
-
-
Algire, G.H.1
Chalkley, H.W.2
-
3
-
-
0026846928
-
The role of angiogenesis in tumor growth
-
Folkman J (1992) The role of angiogenesis in tumor growth. Semin Cancer Biol 3:65-71
-
(1992)
Semin Cancer Biol
, vol.3
, pp. 65-71
-
-
Folkman, J.1
-
4
-
-
0036984640
-
Role of angiogenesis in tumor growth and metastasis
-
Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15-18
-
(2002)
Semin Oncol
, vol.29
, pp. 15-18
-
-
Folkman, J.1
-
5
-
-
85013312416
-
Tumor angiogenesis: Therapeutic implications
-
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
-
(1971)
N Engl J Med
, vol.285
, pp. 1182-1186
-
-
Folkman, J.1
-
6
-
-
76049088643
-
Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer
-
Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM et al (2010) Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 76:824-830
-
(2010)
Int J Radiat Oncol Biol Phys
, vol.76
, pp. 824-830
-
-
Crane, C.H.1
Eng, C.2
Feig, B.W.3
Das, P.4
Skibber, J.M.5
Chang, G.J.6
Wolff, R.A.7
Krishnan, S.8
Hamilton, S.9
Janjan, N.A.10
Maru, D.M.11
Ellis, L.M.12
-
7
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
DOI 10.1056/NEJMoa032691
-
Hurwitz H, Fehrenbacher L, NovotnyW, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342 (Pubitemid 38702844)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
8
-
-
1542319129
-
Cancer without disease
-
DOI 10.1038/427787a
-
Folkman J, Kalluri R (2004) Cancer without disease. Nature 427:787 (Pubitemid 38297724)
-
(2004)
Nature
, vol.427
, Issue.6977
, pp. 787
-
-
Folkman, J.1
Kalluri, R.2
-
9
-
-
33845767868
-
Macrophages regulate the angiogenic switch in a mouse model of breast cancer
-
DOI 10.1158/0008-5472.CAN-06-1278
-
Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66:11238-11246 (Pubitemid 46009952)
-
(2006)
Cancer Research
, vol.66
, Issue.23
, pp. 11238-11246
-
-
Lin, E.Y.1
Li, J.-F.2
Gnatovskiy, L.3
Deng, Y.4
Zhu, L.5
Grzesik, D.A.6
Qian, H.7
Xue, X.-N.8
Pollard, J.W.9
-
10
-
-
34249979533
-
Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer
-
DOI 10.1182/blood-2006-10-053504
-
Venneri MA, De PM, Ponzoni M, Pucci F, Scielzo C, Zonari E, Mazzieri R, Doglioni C, Naldini L (2007) Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 109:5276-5285 (Pubitemid 46890548)
-
(2007)
Blood
, vol.109
, Issue.12
, pp. 5276-5285
-
-
Venneri, M.A.1
De Palma, M.2
Ponzoni, M.3
Pucci, F.4
Scielzo, C.5
Zonari, E.6
Mazzieri, R.7
Doglioni, C.8
Naldini, L.9
-
11
-
-
34548798765
-
Tie2-expressing monocytes and tumor angiogenesis: Regulation by hypoxia and angiopoietin-2
-
DOI 10.1158/0008-5472.CAN-07-1684
-
Lewis CE, De PM, Naldini L (2007) Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res 67:8429-8432 (Pubitemid 47437413)
-
(2007)
Cancer Research
, vol.67
, Issue.18
, pp. 8429-8432
-
-
Lewis, C.E.1
De Palma, M.2
Naldini, L.3
-
12
-
-
77952090934
-
EPCs and pathological angiogenesis: When good cells go bad
-
Li CS, Neu MB, Shaw LC, Kielczewski JL, Moldovan NI, Grant MB (2010) EPCs and pathological angiogenesis: when good cells go bad. Microvasc Res 79:207-216
-
(2010)
Microvasc Res
, vol.79
, pp. 207-216
-
-
Li, C.S.1
Neu, M.B.2
Shaw, L.C.3
Kielczewski, J.L.4
Moldovan, N.I.5
Grant, M.B.6
-
13
-
-
0024818355
-
Vascular endothelial growth factor is a secreted angiogenic mitogen
-
Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309 (Pubitemid 20066716)
-
(1989)
Science
, vol.246
, Issue.4935
, pp. 1306-1309
-
-
Leung, D.W.1
Cachianes, G.2
Kuang, W.-J.3
Goeddel, D.V.4
Ferrara, N.5
-
14
-
-
3843150503
-
Vascular endothelial growth factor in esophageal cancer
-
DOI 10.1002/jso.20070
-
Kleespies A, Guba M, Jauch KW, Bruns CJ (2004) Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 87:95-104 (Pubitemid 39079657)
-
(2004)
Journal of Surgical Oncology
, vol.87
, Issue.2
, pp. 95-104
-
-
Kleespies, A.1
Guba, M.2
Jauch, K.-W.3
Bruns, C.J.4
-
15
-
-
7444260919
-
Vascular endothelial growth factor in colorectal cancer
-
DOI 10.1007/s00384-003-0576-y
-
Guba M, Seeliger H, Kleespies A, Jauch KW, Bruns C (2004) Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis 19:510-517 (Pubitemid 39445405)
-
(2004)
International Journal of Colorectal Disease
, vol.19
, Issue.6
, pp. 510-517
-
-
Guba, M.1
Seeliger, H.2
Kleespies, A.3
Jauch, K.-W.4
Bruns, C.5
-
16
-
-
14644440555
-
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
-
DOI 10.1200/JCO.2005.06.081
-
Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027 (Pubitemid 46202320)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.5
, pp. 1011-1027
-
-
Hicklin, D.J.1
Ellis, L.M.2
-
17
-
-
79851496674
-
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer
-
Wong NS, Fernando NH, Nixon AB, Cushman S, Aklilu M, Bendell JC, Morse MA, Blobe GC, Ashton J, Pang H, Hurwitz HI (2011) A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res 31:255-261
-
(2011)
Anticancer Res
, vol.31
, pp. 255-261
-
-
Wong, N.S.1
Fernando, N.H.2
Nixon, A.B.3
Cushman, S.4
Aklilu, M.5
Bendell, J.C.6
Morse, M.A.7
Blobe, G.C.8
Ashton, J.9
Pang, H.10
Hurwitz, H.I.11
-
18
-
-
34447130180
-
FDA drug approval summary: Bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer
-
DOI 10.1634/theoncologist.12-6-713
-
Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12:713-718 (Pubitemid 47036205)
-
(2007)
Oncologist
, vol.12
, Issue.6
, pp. 713-718
-
-
Cohen, M.H.1
Gootenberg, J.2
Keegan, P.3
Pazdur, R.4
-
19
-
-
82755183572
-
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial
-
Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931-1939
-
(2011)
Lancet
, vol.378
, pp. 1931-1939
-
-
Rini, B.I.1
Escudier, B.2
Tomczak, P.3
Kaprin, A.4
Szczylik, C.5
Hutson, T.E.6
Michaelson, M.D.7
Gorbunova, V.A.8
Gore, M.E.9
Rusakov, I.G.10
Negrier, S.11
Ou, Y.C.12
-
20
-
-
0030856731
-
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
-
Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599 (Pubitemid 27441066)
-
(1997)
Cancer Research
, vol.57
, Issue.20
, pp. 4593-4599
-
-
Presta, L.G.1
Chen, H.2
O'Connor, S.J.3
Chisholm, V.4
Meng, Y.G.5
Krummen, L.6
Winkler, M.7
Ferrara, N.8
-
21
-
-
77950494294
-
Effect of bevacizumab in older patients with metastatic colorectal cancer: Pooled analysis of four randomized studies
-
Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr UP (2010) Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 136:737-743
-
(2010)
J Cancer Res Clin Oncol
, vol.136
, pp. 737-743
-
-
Cassidy, J.1
Saltz, L.B.2
Giantonio, B.J.3
Kabbinavar, F.F.4
Hurwitz, H.I.5
Rohr, U.P.6
-
22
-
-
84856239169
-
Cerebrovascular events after bevacizumab treatment: An early and severe complication
-
Seet RC, Rabinstein AA, Lindell PE, Uhm JH, Wijdicks EF (2011) Cerebrovascular events after bevacizumab treatment: an early and severe complication. Neurocritical Care 15:421-427
-
(2011)
Neurocritical Care
, vol.15
, pp. 421-427
-
-
Seet, R.C.1
Rabinstein, A.A.2
Lindell, P.E.3
Uhm, J.H.4
Wijdicks, E.F.5
-
23
-
-
80052197143
-
A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer
-
Altomare I, Bendell JC, Bullock KE, Uronis HE, Morse MA, Hsu SD, Zafar SY, Blobe GC, Pang H, HoneycuttW, Sutton L, Hurwitz HI (2011) A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist 16:1131-1137
-
(2011)
Oncologist
, vol.16
, pp. 1131-1137
-
-
Altomare, I.1
Bendell, J.C.2
Bullock, K.E.3
Uronis, H.E.4
Morse, M.A.5
Hsu, S.D.6
Zafar, S.Y.7
Blobe, G.C.8
Pang, H.9
Honeycutt, W.10
Sutton, L.11
Hurwitz, H.I.12
-
24
-
-
77954682879
-
Ramucirumab (IMC-1121B): A novel attack on angiogenesis
-
Spratlin JL, Mulder KE, Mackey JR (2010) Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol 6:1085-1094
-
(2010)
Future Oncol
, vol.6
, pp. 1085-1094
-
-
Spratlin, J.L.1
Mulder, K.E.2
MacKey, J.R.3
-
25
-
-
0037137903
-
Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy
-
DOI 10.1002/ijc.1634
-
Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z (2002) Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer 97:393-399 (Pubitemid 34049034)
-
(2002)
International Journal of Cancer
, vol.97
, Issue.3
, pp. 393-399
-
-
Lu, D.1
Jimenez, X.2
Zhang, H.3
Bohlen, P.4
Witte, L.5
Zhu, Z.6
-
26
-
-
4944249117
-
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
DOI 10.1158/0008-5472.CAN-04-1443
-
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109 (Pubitemid 39331023)
-
(2004)
Cancer Research
, vol.64
, Issue.19
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
Wilkie, D.4
McNabola, A.5
Rong, H.6
Chen, C.7
Zhang, X.8
Vincent, P.9
McHugh, M.10
Cao, Y.11
Shujath, J.12
Gawlak, S.13
Eveleigh, D.14
Rowley, B.15
Liu, L.16
Adnane, L.17
Lynch, M.18
Auclair, D.19
Taylor, I.20
Gedrich, R.21
Voznesensky, A.22
Riedl, B.23
Post, L.E.24
Bollag, G.25
Trail, P.A.26
more..
-
28
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
Hilgard, P.4
Gane, E.5
Blanc, J.F.6
De Oliveira, A.C.7
Santoro, A.8
Raoul, J.L.9
Forner, A.10
Schwartz, M.11
Porta, C.12
-
29
-
-
79955845255
-
Targeted therapies for the treatment of metastatic renal cell carcinoma: Clinical evidence
-
Hutson TE (2011) Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 16(Suppl 2):14-22
-
(2011)
Oncologist
, vol.16
, Issue.SUPPL. 2
, pp. 14-22
-
-
Hutson, T.E.1
-
31
-
-
77953725220
-
Targeted treatments in colorectal cancer: State of the art and future perspectives
-
Arnold D, Seufferlein T (2010) Targeted treatments in colorectal cancer: state of the art and future perspectives. Gut 59:838-858
-
(2010)
Gut
, vol.59
, pp. 838-858
-
-
Arnold, D.1
Seufferlein, T.2
-
32
-
-
79952697854
-
Targeting mTOR in cancer: Renal cell is just a beginning
-
Azim H, Azim HA Jr, Escudier B (2010) Targeting mTOR in cancer: renal cell is just a beginning. Target Oncol 5:269-280
-
(2010)
Target Oncol
, vol.5
, pp. 269-280
-
-
Azim, H.1
Azim Jr., H.A.2
Escudier, B.3
-
33
-
-
20344367537
-
Tumour vascular targeting
-
DOI 10.1038/nrc1627
-
Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev Cancer 5:436-446 (Pubitemid 40791486)
-
(2005)
Nature Reviews Cancer
, vol.5
, Issue.6
, pp. 436-446
-
-
Neri, D.1
Bicknell, R.2
-
34
-
-
33749005405
-
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors
-
DOI 10.1126/science.1127592
-
Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313:1785-1787 (Pubitemid 44454154)
-
(2006)
Science
, vol.313
, Issue.5794
, pp. 1785-1787
-
-
Shaked, Y.1
Ciarrocchi, A.2
Franco, M.3
Lee, C.R.4
Man, S.5
Cheung, A.M.6
Hicklin, D.J.7
Chaplin, D.8
Foster, F.S.9
Benezra, R.10
Kerbel, R.S.11
-
35
-
-
0142155561
-
Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response
-
DOI 10.1016/S0360-3016(03)00769-7
-
Horsman MR, Murata R (2003) Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 57:1047-1055 (Pubitemid 37324123)
-
(2003)
International Journal of Radiation Oncology Biology Physics
, vol.57
, Issue.4
, pp. 1047-1055
-
-
Horsman, M.R.1
Murata, R.2
-
36
-
-
79551570717
-
Classification and toxicities of vascular disrupting agents
-
Hasani A, Leighl N (2011) Classification and toxicities of vascular disrupting agents. Clin Lung Cancer 12:18-25
-
(2011)
Clin Lung Cancer
, vol.12
, pp. 18-25
-
-
Hasani, A.1
Leighl, N.2
-
37
-
-
79953648492
-
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer
-
Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J, Shreeves G, Poupard L, Lu SP, Balkissoon J, Chaplin DJ, Rustin GJ (2011) Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 22:2036-2041
-
(2011)
Ann Oncol
, vol.22
, pp. 2036-2041
-
-
Zweifel, M.1
Jayson, G.C.2
Reed, N.S.3
Osborne, R.4
Hassan, B.5
Ledermann, J.6
Shreeves, G.7
Poupard, L.8
Lu, S.P.9
Balkissoon, J.10
Chaplin, D.J.11
Rustin, G.J.12
-
38
-
-
77954924659
-
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma
-
Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C et al (2010) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28:2712-2718
-
(2010)
J Clin Oncol
, vol.28
, pp. 2712-2718
-
-
Stupp, R.1
Hegi, M.E.2
Neyns, B.3
Goldbrunner, R.4
Schlegel, U.5
Clement, P.M.6
Grabenbauer, G.G.7
Ochsenbein, A.F.8
Simon, M.9
Dietrich, P.Y.10
Pietsch, T.11
Hicking, C.12
-
39
-
-
0000172793
-
Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice
-
Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, Hanahan D, McDonald DM (1998) Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 101:1401-1413 (Pubitemid 28166838)
-
(1998)
Journal of Clinical Investigation
, vol.101
, Issue.7
, pp. 1401-1413
-
-
Thurston, G.1
McLean, J.W.2
Rizen, M.3
Baluk, P.4
Haskell, A.5
Murphy, T.J.6
Hanahan, D.7
McDonald, D.M.8
-
40
-
-
74049087050
-
Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer
-
Eichhorn ME, Ischenko I, Luedemann S, Strieth S, Papyan A, Werner A, Bohnenkamp H, Guenzi E, Preissler G, Michaelis U, Jauch KW, Bruns CJ et al (2010) Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer 126:1235-1245
-
(2010)
Int J Cancer
, vol.126
, pp. 1235-1245
-
-
Eichhorn, M.E.1
Ischenko, I.2
Luedemann, S.3
Strieth, S.4
Papyan, A.5
Werner, A.6
Bohnenkamp, H.7
Guenzi, E.8
Preissler, G.9
Michaelis, U.10
Jauch, K.W.11
Bruns, C.J.12
-
41
-
-
84860463458
-
Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: A randomized controlled phase II trial
-
doi:10.1093/ annonc/mdr379
-
Lohr JM, Haas SL, Bechstein WO, Bodoky G, Cwiertka K, Fischbach W, Folsch UR, Jager D, Osinsky D, Prausova J, Schmidt WE, Lutz MP (2011) Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Ann Oncol. doi:10.1093/ annonc/mdr379
-
(2011)
Ann Oncol
-
-
Lohr, J.M.1
Haas, S.L.2
Bechstein, W.O.3
Bodoky, G.4
Cwiertka, K.5
Fischbach, W.6
Folsch, U.R.7
Jager, D.8
Osinsky, D.9
Prausova, J.10
Schmidt, W.E.11
Lutz, M.P.12
-
42
-
-
79953189584
-
Current approach in the treatment of hepatocellular carcinoma
-
Rossi L, Zoratto F, Papa A, Iodice F, Minozzi M, Frati L, Tomao S (2010) Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol 2:348-359
-
(2010)
World J Gastrointest Oncol
, vol.2
, pp. 348-359
-
-
Rossi, L.1
Zoratto, F.2
Papa, A.3
Iodice, F.4
Minozzi, M.5
Frati, L.6
Tomao, S.7
-
43
-
-
80855144261
-
Combination therapy for renal cell cancer: What are possible options?
-
Santos N, Wenger JB, Havre P, Liu Y, Dagan R, Imanirad I, Ivey AM, Zlotecki RA, Algood CB, Gilbert SM, Allegra CJ, Okunieff Pet al (2011) Combination therapy for renal cell cancer: what are possible options? Oncology 81:220-229
-
(2011)
Oncology
, vol.81
, pp. 220-229
-
-
Santos, N.1
Wenger, J.B.2
Havre, P.3
Liu, Y.4
Dagan, R.5
Imanirad, I.6
Ivey, A.M.7
Zlotecki, R.A.8
Algood, C.B.9
Gilbert, S.M.10
Allegra, C.J.11
Pet Al., O.12
-
44
-
-
33744466541
-
Antiangiogenic therapy: A universal chemosensitization strategy for cancer?
-
DOI 10.1126/science.1125950
-
Kerbel RS (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312:1171-1175 (Pubitemid 43801134)
-
(2006)
Science
, vol.312
, Issue.5777
, pp. 1171-1175
-
-
Kerbel, R.S.1
-
45
-
-
0842304140
-
Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis
-
Huang J, Soffer SZ, Kim ES, McCrudden KW, Huang J, New T, Manley CA, Middlesworth W, O'Toole K, Yamashiro DJ, Kandel JJ (2004) Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res 2:36-42 (Pubitemid 38167106)
-
(2004)
Molecular Cancer Research
, vol.2
, Issue.1
, pp. 36-42
-
-
Huang, J.1
Softer, S.Z.2
Kim, E.S.3
McCrudden, K.W.4
Huang, J.5
New, T.6
Manley, C.A.7
Middlesworth, W.8
O'Toole, K.9
Yamashiro, D.J.10
Kandel, J.J.11
-
46
-
-
0034796595
-
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
-
DOI 10.1038/nm0901-987
-
Jain RK (2001) Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-989 (Pubitemid 32937367)
-
(2001)
Nature Medicine
, vol.7
, Issue.9
, pp. 987-989
-
-
Jain, R.K.1
-
47
-
-
79551642429
-
Angiogenesis inhibitors: Implications for combination with conventional therapies
-
Moschetta M, Cesca M, Pretto F, Giavazzi R (2010) Angiogenesis inhibitors: implications for combination with conventional therapies. Curr Pharm Des 16:3921-3931
-
(2010)
Curr Pharm des
, vol.16
, pp. 3921-3931
-
-
Moschetta, M.1
Cesca, M.2
Pretto, F.3
Giavazzi, R.4
-
48
-
-
33847638137
-
Estimates of the cancer incidence and mortality in Europe in 2006
-
DOI 10.1093/annonc/mdl498
-
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581-592 (Pubitemid 46359643)
-
(2007)
Annals of Oncology
, vol.18
, Issue.3
, pp. 581-592
-
-
Ferlay, J.1
Autier, P.2
Boniol, M.3
Heanue, M.4
Colombet, M.5
Boyle, P.6
-
49
-
-
19144366561
-
Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor
-
Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T, Ishigami S, Toda Y, Nakayama H, Fukumoto M, Fujita J, Imamura M (1996) Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 23:455-464 (Pubitemid 26087158)
-
(1996)
Hepatology
, vol.23
, Issue.3
, pp. 455-464
-
-
Mise, M.1
Arii, S.2
Higashituji, H.3
Furutani, M.4
Niwano, M.5
Harada, T.6
Ishigami, S.-I.7
Toda, Y.8
Nakayama, H.9
Fukumoto, M.10
Fujita, J.11
Imamura, M.12
-
50
-
-
33751115483
-
Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma
-
Li Q, Xu B, Fu L, Hao XS (2006) Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma. J Exp Clin Cancer Res 25:403-409 (Pubitemid 44763732)
-
(2006)
Journal of Experimental and Clinical Cancer Research
, vol.25
, Issue.3
, pp. 403-409
-
-
Li, Q.1
Xu, B.2
Fu, L.3
Hao, X.S.4
-
51
-
-
60849124241
-
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma
-
Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27:843-850
-
(2009)
J Clin Oncol
, vol.27
, pp. 843-850
-
-
Thomas, M.B.1
Morris, J.S.2
Chadha, R.3
Iwasaki, M.4
Kaur, H.5
Lin, E.6
Kaseb, A.7
Glover, K.8
Davila, M.9
Abbruzzese, J.10
-
52
-
-
77949890945
-
Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
-
Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E,Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061-1068
-
(2010)
J Clin Oncol
, vol.28
, pp. 1061-1068
-
-
Sternberg, C.N.1
Davis, I.D.2
Mardiak, J.3
Szczylik, C.4
Lee, E.5
Wagstaff, J.6
Barrios, C.H.7
Salman, P.8
Gladkov, O.A.9
Kavina, A.10
Zarba, J.J.11
Chen, M.12
-
53
-
-
77952318310
-
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206
-
Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28:2137-2143
-
(2010)
J Clin Oncol
, vol.28
, pp. 2137-2143
-
-
Rini, B.I.1
Halabi, S.2
Rosenberg, J.E.3
Stadler, W.M.4
Vaena, D.A.5
Archer, L.6
Atkins, J.N.7
Picus, J.8
Czaykowski, P.9
Dutcher, J.10
Small, E.J.11
-
54
-
-
78650373860
-
Hypoxia and hypoxia-inducible factors: Master regulators of metastasis
-
Lu X, Kang Y (2010) Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 16:5928-5935
-
(2010)
Clin Cancer Res
, vol.16
, pp. 5928-5935
-
-
Lu, X.1
Kang, Y.2
-
55
-
-
66749114931
-
MTOR in renal cell cancer: Modulator of tumor biology and therapeutic target
-
Wysocki PJ (2009) mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev Mol Diagn 9:231-241
-
(2009)
Expert Rev Mol Diagn
, vol.9
, pp. 231-241
-
-
Wysocki, P.J.1
-
56
-
-
77952301116
-
Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma
-
Hainsworth JD, Spigel DR, Burris HA III, Waterhouse D, Clark BL, Whorf R (2010) Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 28:2131-2136
-
(2010)
J Clin Oncol
, vol.28
, pp. 2131-2136
-
-
Hainsworth, J.D.1
Spigel, D.R.2
Burris, H.A.3
Waterhouse, D.4
Clark, B.L.5
Whorf, R.6
-
57
-
-
76049128595
-
Estimates of cancer incidence and mortality in Europe in 2008
-
Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765-781
-
(2010)
Eur J Cancer
, vol.46
, pp. 765-781
-
-
Ferlay, J.1
Parkin, D.M.2
Steliarova-Foucher, E.3
-
58
-
-
72549116624
-
Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: Vasculature-independent radiosensitizing effect of bevacizumab
-
Koukourakis MI,Giatromanolaki A, Sheldon H, Buffa FM, Kouklakis G, Ragoussis I, Sivridis E, Harris AL (2009) Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab. Clin Cancer Res 15:7069-7076
-
(2009)
Clin Cancer Res
, vol.15
, pp. 7069-7076
-
-
Koukourakis, M.I.1
Giatromanolaki, A.2
Sheldon, H.3
Buffa, F.M.4
Kouklakis, G.5
Ragoussis, I.6
Sivridis, E.7
Harris, A.L.8
-
59
-
-
81255142967
-
Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer
-
Koukourakis GV, Sotiropoulou-Lontou A (2011) Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer. Clin Transl Oncol 13:710-714
-
(2011)
Clin Transl Oncol
, vol.13
, pp. 710-714
-
-
Koukourakis, G.V.1
Sotiropoulou-Lontou, A.2
-
60
-
-
74949119167
-
Phase i study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors
-
Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA et al (2010) Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 28:207-214
-
(2010)
J Clin Oncol
, vol.28
, pp. 207-214
-
-
Lockhart, A.C.1
Rothenberg, M.L.2
Dupont, J.3
Cooper, W.4
Chevalier, P.5
Sternas, L.6
Buzenet, G.7
Koehler, E.8
Sosman, J.A.9
Schwartz, L.H.10
Gultekin, D.H.11
Koutcher, J.A.12
-
61
-
-
0037143764
-
VEGF-Trap: A VEGF blocker with potent antitumor effects
-
DOI 10.1073/pnas.172398299
-
Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T et al (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393-11398 (Pubitemid 34920936)
-
(2002)
Proceedings of the National Academy of Sciences of the United States of America
, vol.99
, Issue.17
, pp. 11393-11398
-
-
Holash, J.1
Davis, S.2
Papadopoulos, N.3
Croll, S.D.4
Ho, L.5
Russell, M.6
Boland, P.7
Leidich, R.8
Hylton, D.9
Burova, E.10
Ioffe, E.11
Huang, T.12
Radziejewski, C.13
Bailey, K.14
Fandl, J.P.15
Daly, T.16
Wiegand, S.J.17
Yancopoulos, G.D.18
Rudge, J.S.19
-
62
-
-
84861190138
-
A preclinical and clinical review of aflibercept for the management of cancer
-
press
-
Gaya A, Tse V (2012) A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev (in press)
-
(2012)
Cancer Treat Rev
-
-
Gaya, A.1
Tse, V.2
-
63
-
-
77957083400
-
Clinical applications of VEGF-trap (aflibercept) in cancer treatment
-
Teng LS, Jin KT, He KF, Zhang J,Wang HH, Cao J (2010) Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc 73:449-456
-
(2010)
J Chin Med Assoc
, vol.73
, pp. 449-456
-
-
Teng, L.S.1
Jin, K.T.2
He, K.F.3
Zhang, J.4
Wang, H.H.5
Cao, J.6
-
64
-
-
84863011440
-
Aflibercept in the treatment of metastatic colorectal cancer
-
Wang TF, Lockhart AC (2012) Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol 6:19-30
-
(2012)
Clin Med Insights Oncol
, vol.6
, pp. 19-30
-
-
Wang, T.F.1
Lockhart, A.C.2
-
65
-
-
77958198446
-
Aflibercept (VEGF Trap): One more double-edged sword of anti-VEGF therapy for cancer?
-
Jin K, Shen Y, He K, Xu Z, Li G, Teng L (2010) Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer? Clin Transl Oncol 12:526-532
-
(2010)
Clin Transl Oncol
, vol.12
, pp. 526-532
-
-
Jin, K.1
Shen, Y.2
He, K.3
Xu, Z.4
Li, G.5
Teng, L.6
-
66
-
-
83455198239
-
Pancreatic cancer: Overview of descriptive epidemiology
-
Bosetti C, Bertuccio P, Negri E, La VC, Zeegers MP, Boffetta P (2012) Pancreatic cancer: overview of descriptive epidemiology. Mol Carcinog 51:3-13
-
(2012)
Mol Carcinog
, vol.51
, pp. 3-13
-
-
Bosetti, C.1
Bertuccio, P.2
Negri, E.3
La, V.C.4
Zeegers, M.P.5
Boffetta, P.6
-
67
-
-
53549092538
-
Targeting angiogenesis in pancreatic cancer: Rationale and pitfalls
-
Whipple C, Korc M (2008) Targeting angiogenesis in pancreatic cancer: rationale and pitfalls. Langenbecks Arch Surg 393:901-910
-
(2008)
Langenbecks Arch Surg
, vol.393
, pp. 901-910
-
-
Whipple, C.1
Korc, M.2
-
68
-
-
70649098156
-
Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/ cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer-A multi-centre randomised phase II stud
-
Wilkowski R, Boeck S, Ostermaier S, Sauer R, Herbst M, Fietkau R, Flentje M, Miethe S, Boettcher HD, Scholten T, Bruns CJ, Rau HG et al (2009) Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/ cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer-a multi-centre randomised phase II stud. Br J Cancer 101:1853-1859
-
(2009)
Br J Cancer
, vol.101
, pp. 1853-1859
-
-
Wilkowski, R.1
Boeck, S.2
Ostermaier, S.3
Sauer, R.4
Herbst, M.5
Fietkau, R.6
Flentje, M.7
Miethe, S.8
Boettcher, H.D.9
Scholten, T.10
Bruns, C.J.11
Rau, H.G.12
-
69
-
-
84855244327
-
Chemotherapy of metastatic pancreatic adenocarcinoma: Challenges and encouraging results
-
Conroy T, Mitry E (2011) Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results. Bull Cancer 98:1439-1446
-
(2011)
Bull Cancer
, vol.98
, pp. 1439-1446
-
-
Conroy, T.1
Mitry, E.2
-
70
-
-
79958119999
-
Anti-angiogenic agents in pancreatic cancer: A review
-
Assifi MM, Hines OJ (2011) Anti-angiogenic agents in pancreatic cancer: a review. Anticancer Agents Med Chem 11:464-469
-
(2011)
Anticancer Agents Med Chem
, vol.11
, pp. 464-469
-
-
Assifi, M.M.1
Hines, O.J.2
-
71
-
-
84864365642
-
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer
-
doi:10.1007/ s10637-011-9658-9
-
El-Khoueiry AB, Ramanathan RK, Yang DY, Zhang W, Shibata S, Wright JJ, Gandara D, Lenz HJ (2011) A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Investig New Drugs. doi:10.1007/ s10637-011-9658-9
-
(2011)
Investig New Drugs
-
-
El-Khoueiry, A.B.1
Ramanathan, R.K.2
Yang, D.Y.3
Zhang, W.4
Shibata, S.5
Wright, J.J.6
Gandara, D.7
Lenz, H.J.8
-
72
-
-
79952036599
-
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomised phase 3 study
-
Kindler HL, Ioka T, Richel DJ, Bennouna J, Letourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM,Wasan HS et al (2011)Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 12:256-262
-
(2011)
Lancet Oncol
, vol.12
, pp. 256-262
-
-
Kindler, H.L.1
Ioka, T.2
Richel, D.J.3
Bennouna, J.4
Letourneau, R.5
Okusaka, T.6
Funakoshi, A.7
Furuse, J.8
Park, Y.S.9
Ohkawa, S.10
Springett, G.M.11
Wasan, H.S.12
-
73
-
-
84866733344
-
Phase i study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer
-
Spano JP, Moore MJ, Pithavala YK, Ricart AD, Kim S, Rixe O (2011) Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Investig New Drugs
-
(2011)
Investig New Drugs
-
-
Spano, J.P.1
Moore, M.J.2
Pithavala, Y.K.3
Ricart, A.D.4
Kim, S.5
Rixe, O.6
-
74
-
-
65549150854
-
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
-
Van CE, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231-2237
-
(2009)
J Clin Oncol
, vol.27
, pp. 2231-2237
-
-
Van, C.E.1
Vervenne, W.L.2
Bennouna, J.3
Humblet, Y.4
Gill, S.5
Van Laethem, J.L.6
Verslype, C.7
Scheithauer, W.8
Shang, A.9
Cosaert, J.10
Moore, M.J.11
-
75
-
-
80052886108
-
Emerging pathways and future targets for the molecular therapy of pancreatic cancer
-
Vaccaro V, Melisi D, Bria E, Cuppone F, Ciuffreda L, Pino MS, Gelibter A, Tortora G, Cognetti F, Milella M (2011) Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opin Ther Targets 15:1183-1196
-
(2011)
Expert Opin Ther Targets
, vol.15
, pp. 1183-1196
-
-
Vaccaro, V.1
Melisi, D.2
Bria, E.3
Cuppone, F.4
Ciuffreda, L.5
Pino, M.S.6
Gelibter, A.7
Tortora, G.8
Cognetti, F.9
Milella, M.10
-
76
-
-
72549089933
-
Pancreatic cancer stem cells: New understanding of tumorigenesis, clinical implications
-
Ischenko I, Seeliger H, Kleespies A, Angele MK, Eichhorn ME, Jauch KW, Bruns CJ (2010) Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbecks Arch Surg 395:1-10
-
(2010)
Langenbecks Arch Surg
, vol.395
, pp. 1-10
-
-
Ischenko, I.1
Seeliger, H.2
Kleespies, A.3
Angele, M.K.4
Eichhorn, M.E.5
Jauch, K.W.6
Bruns, C.J.7
-
77
-
-
0030789242
-
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
-
DOI 10.1038/nm0797-730
-
Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-737 (Pubitemid 27298715)
-
(1997)
Nature Medicine
, vol.3
, Issue.7
, pp. 730-737
-
-
Bonnet, D.1
Dick, J.E.2
-
78
-
-
79960982340
-
Cancer stem cells and angiogenesis
-
Zhao Y, Bao Q, Renner A, Camaj P, Eichhorn M, Ischenko I, Angele M, Kleespies A, Jauch KW, Bruns C (2011) Cancer stem cells and angiogenesis. Int J Dev Biol 55:477-482
-
(2011)
Int J Dev Biol
, vol.55
, pp. 477-482
-
-
Zhao, Y.1
Bao, Q.2
Renner, A.3
Camaj, P.4
Eichhorn, M.5
Ischenko, I.6
Angele, M.7
Kleespies, A.8
Jauch, K.W.9
Bruns, C.10
-
79
-
-
80054974211
-
Stem cells, quiescence and rectal carcinoma: An unexplored relationship and potential therapeutic target
-
Buczacki S, Davies RJ, Winton DJ (2011) Stem cells, quiescence and rectal carcinoma: an unexplored relationship and potential therapeutic target. Br J Cancer 105:1253-1259
-
(2011)
Br J Cancer
, vol.105
, pp. 1253-1259
-
-
Buczacki, S.1
Davies, R.J.2
Winton, D.J.3
-
81
-
-
77951224759
-
ABCG2: A potential marker of stem cells and novel target in stem cell and cancer therapy
-
Ding XW, Wu JH, Jiang CP (2010) ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 86:631-637
-
(2010)
Life Sci
, vol.86
, pp. 631-637
-
-
Ding, X.W.1
Wu, J.H.2
Jiang, C.P.3
-
82
-
-
84855293870
-
Comparative evaluation of cancer stem cell markers in normal pancreas and pancreatic ductal adenocarcinoma
-
Vizio B, Mauri FA, Prati A, Trivedi P, Giacobino A, Novarino A, Satolli MA, Ciuffreda L, Camandona M, Gasparri G, Bellone G (2012) Comparative evaluation of cancer stem cell markers in normal pancreas and pancreatic ductal adenocarcinoma. Oncol Rep 27:69-76
-
(2012)
Oncol Rep
, vol.27
, pp. 69-76
-
-
Vizio, B.1
Mauri, F.A.2
Prati, A.3
Trivedi, P.4
Giacobino, A.5
Novarino, A.6
Satolli, M.A.7
Ciuffreda, L.8
Camandona, M.9
Gasparri, G.10
Bellone, G.11
|